Stimuli Technology
Boulogne-Billancourt, FranceFounded 2017
- Neuromodulation
Stimuli Technology develops Tensi+, a medical device for treating overactive bladder. The non-drug, non-invasive treatment uses transcutaneous electrical stimulation of the posterior tibial nerve and is prescribed by a healthcare professional.
- Founded
- 2017
- Employees
- 11–50
reccy insights
The clearest company milestone is its founding in 2017. Stimuli Technology develops Tensi+, a medical device intended to treat overactive bladder symptoms through transcutaneous electrical nerve stimulation of the posterior tibial nerve. The treatment is non-drug and non-invasive, and the device is designed for home use in 20-minute daily sessions, with placement near the inner ankle. Delphine Agullo is identified as CEO.
Written by reccy's AI from company sites, press and funding records · updated Oct 2026
What makes Stimuli Technology distinct
- 01Offers a non-drug, non-invasive treatment for overactive bladder.
- 02Designed for at-home use in 20-minute daily sessions, with the device placed near the inner ankle.
- 03Developed in consultation with urologists, specialists, and patients.
- 04Made in France and covered by French national health insurance when prescribed.
Technology & products
- Tensi+
A medical device that treats overactive bladder symptoms using transcutaneous electrical nerve stimulation of the posterior tibial nerve to modulate bladder-brain communication.
- Tensi+ medical device for overactive bladder symptoms.
- Transcutaneous electrical nerve stimulation targeting the posterior tibial nerve.
Similar companies
About Stimuli Technology
- Products
- Tensi+
- Leadership
- Delphine Agullo, CEO
- Focus areas
- Medical devices, digital health, urology, overactive bladder, neuromodulation, TENS, non-invasive therapy, healthcare
- Headquarters
- Boulogne-Billancourt, France
- Founded
- 2017
- Employees
- 11–50
- Patents granted
- 2
- Trademarks
- 1